A Phase I Dose-Finding Study of Oxaliplatin (NSC 266046) Combined With Continuous Infusion Topotecan Hydrochloride as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Latest Information Update: 28 May 2019
At a glance
- Drugs Oxaliplatin (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 04 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 04 Sep 2005 New trial record.